Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat PK in Renal Impairment
NCT03192111Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of entinostat in cancer (4 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration, Area Under the Concentration-Time Curve from Time 0 to Infinity and 1 more. Started Jul 2017; status: completed.
02
Drugs
entinostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03192111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192111.